» Articles » PMID: 19221438

Astrocyte Elevated Gene-1 Regulates Hepatocellular Carcinoma Development and Progression

Overview
Journal J Clin Invest
Specialty General Medicine
Date 2009 Feb 18
PMID 19221438
Citations 175
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatocellular carcinoma (HCC) is a highly aggressive vascular cancer characterized by diverse etiology, activation of multiple signal transduction pathways, and various gene mutations. Here, we have determined a specific role for astrocyte elevated gene-1 (AEG1) in HCC pathogenesis. Expression of AEG1 was extremely low in human hepatocytes, but its levels were significantly increased in human HCC. Stable overexpression of AEG1 converted nontumorigenic human HCC cells into highly aggressive vascular tumors, and inhibition of AEG1 abrogated tumorigenesis by aggressive HCC cells in a xenograft model of nude mice. In human HCC, AEG1 overexpression was associated with elevated copy numbers. Microarray analysis revealed that AEG1 modulated the expression of genes associated with invasion, metastasis, chemoresistance, angiogenesis, and senescence. AEG1 also was found to activate Wnt/beta-catenin signaling via ERK42/44 activation and upregulated lymphoid-enhancing factor 1/T cell factor 1 (LEF1/TCF1), the ultimate executor of the Wnt pathway, important for HCC progression. Inhibition studies further demonstrated that activation of Wnt signaling played a key role in mediating AEG1 function. AEG1 also activated the NF-kappaB pathway, which may play a role in the chronic inflammatory changes preceding HCC development. These data indicate that AEG1 plays a central role in regulating diverse aspects of HCC pathogenesis. Targeted inhibition of AEG1 might lead to the shutdown of key elemental characteristics of HCC and could lead to an effective therapeutic strategy for HCC.

Citing Articles

Metadherin-driven promotion of cancer stem cell phenotypes and its effect on immunity in hepatocellular carcinoma.

Todorovic N, Amedei A World J Gastroenterol. 2024; 30(20):2624-2628.

PMID: 38855151 PMC: 11154677. DOI: 10.3748/wjg.v30.i20.2624.


AEG-1 as a Novel Therapeutic Target in Colon Cancer: A Study from Silencing AEG-1 in BALB/c Mice to Large Data Analysis.

Sriramulu S, Malayaperumal S, Banerjee A, Anbalagan M, Kumar M, Radha R Curr Gene Ther. 2024; 24(4):307-320.

PMID: 38783530 DOI: 10.2174/0115665232273077240104045022.


Metadherin promotes stem cell phenotypes and correlated with immune infiltration in hepatocellular carcinoma.

Wang Y, Shen M, Gao J World J Gastroenterol. 2024; 30(8):901-918.

PMID: 38516242 PMC: 10950638. DOI: 10.3748/wjg.v30.i8.901.


Intracellular Delivery of Stabilized Peptide Blocking MTDH-SND1 Interaction for Breast Cancer Suppression.

Chen H, Zhan M, Zhang Y, Liu J, Wang R, An Y JACS Au. 2024; 4(1):139-149.

PMID: 38274259 PMC: 10806767. DOI: 10.1021/jacsau.3c00573.


Using the metabolite alterations monitoring the AEG-1 expression level and cell biological behaviour of U251 cell in vitro.

Sheng Y, Yin D, Zeng Q PLoS One. 2023; 18(9):e0291092.

PMID: 37656734 PMC: 10473485. DOI: 10.1371/journal.pone.0291092.


References
1.
Harada N, Oshima H, Katoh M, Tamai Y, Oshima M, Taketo M . Hepatocarcinogenesis in mice with beta-catenin and Ha-ras gene mutations. Cancer Res. 2004; 64(1):48-54. DOI: 10.1158/0008-5472.can-03-2123. View

2.
Chiang D, Villanueva A, Hoshida Y, Peix J, Newell P, Minguez B . Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res. 2008; 68(16):6779-88. PMC: 2587454. DOI: 10.1158/0008-5472.CAN-08-0742. View

3.
Zhu A, Blaszkowsky L, Ryan D, Clark J, Muzikansky A, Horgan K . Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006; 24(12):1898-903. DOI: 10.1200/JCO.2005.04.9130. View

4.
Pinson K, Brennan J, Monkley S, Avery B, Skarnes W . An LDL-receptor-related protein mediates Wnt signalling in mice. Nature. 2000; 407(6803):535-8. DOI: 10.1038/35035124. View

5.
Simpson D, Keating G . Sorafenib: in hepatocellular carcinoma. Drugs. 2008; 68(2):251-8. DOI: 10.2165/00003495-200868020-00007. View